Your browser doesn't support javascript.
loading
Disease Progression and Sphingolipids and Neurofilament Light Chain in Early Idiopathic Parkinson's Disease.
Couto, Blas; Sousa, Mario; Gonzalez-Latapi, Paulina; McArthur, Eric; Lang, Anthony; Chen-Plotkin, Alice; Marras, Connie.
Afiliación
  • Couto B; Edmond J. Safra Program in Parkinson's Disease, Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
  • Sousa M; Institute of Cognitive and Traslational Neuroscience (INCyT), at the INECO-CONICET-Favaloro University Hospital, Buenos Aires, Argentina.
  • Gonzalez-Latapi P; Department of Neurology, Inselspital, Bern University Hospital, Bern, Switzerland.
  • McArthur E; Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
  • Lang A; Ken and Ruth Davee Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
  • Chen-Plotkin A; London Health Sciences Centre, London, ON, Canada.
  • Marras C; Edmond J. Safra Program in Parkinson's Disease, Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
Can J Neurol Sci ; : 1-4, 2023 Aug 29.
Article en En | MEDLINE | ID: mdl-37641969
ABSTRACT
Parkinson's disease(PD) lacks a biomarker for disease progression. To analyze how cerebrospinal fluid (CSF), glucosylceramide (GlcCer), sphingomyelin (SM), or serum neurofilament light chain (NfL) associate with progression of PD in a retrospective cohort, we used linear mixed-model regressions between baseline biomarkers and change in dopamine transporter brain-imaging (DaTscan©), Montreal cognitive assesment (MoCA), or global composite outcome (GCO) score. In 191 PD patients, biomarkers were not associated with DaTscan or MoCA change over 2.1 years. Higher baseline GlcCer/SM ratio and serum-NfL nonsignificantly associated with increase in GCO score. Results do not support a role for CSF-sphingolipid/serum-NfL to predict cognitive and DaTscan progression in early-PD. Potential prediction of global clinical change warrants further study.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Can J Neurol Sci Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Can J Neurol Sci Año: 2023 Tipo del documento: Article País de afiliación: Canadá